The abstract is read at the publisher; the summary is JClub's.
Medicare’s ESRD Treatment Choices Model showed no definitive statistically significant improvements in timely kidney transplant referral, evaluation, waitlisting, or living-donor transplantation in Georgia, North Carolina, and South Carolina.
- Why it matters: The ETC Model aims to improve transplant access, but early findings showed no gains in waitlisting or transplantation, leaving uncertainty about whether dialysis-facility incentives affect upstream access steps.
- What they did: Using linked U.S. registry data, difference-in-differences compared ETC versus control facilities for 26,809 adult Traditional Medicare beneficiaries initiating dialysis in 2015–2019 versus 2021–2023, assessing referral within 1 year, evaluation within 6 months, and waitlisting/living-donor transplantation within 2 years.
- The result: Adjusted differential increases were 3.58 percentage points for timely referral (95% CI, -1.30 to 8.45), 8.52 for evaluation initiation (95% CI, -1.42 to 18.45), and 3.61 for waitlisting or living-donor transplantation (95% CI, -0.26 to 7.48), with time-to-event results consistent and COVID-era delays present in both groups.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.